AKT1 and breast carcinoma: We have now used one of these, a potent and specific inhibitor of Akt1 and Akt2 (AKTi-1/2), to study the role of Akt activation in breast cancers and to explore whether Akt inhibition is feasible as a therapeutic strategy.